We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
58 hedge funds and large institutions have $416M invested in Crescent Biopharma in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
67% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 15
23% more capital invested
Capital invested by funds: $338M → $416M (+$78M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.07% less ownership
Funds ownership: 0.98% → 0.91% (-0.07%)
16% less funds holding
Funds holding: 69 → 58 (-11)
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $195K
Holders
58
Holders Change
-11
Holders Change %
-15.94%
% of All Funds
1.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
6
Increased
25
Reduced
15
Closed
16
Calls
–
Puts
$195K
Net Calls
-$195K
Net Calls Change
+$584K
Top Buyers
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$7.21M |
| 2 |
NC
Nexthera Capital
New York
|
+$3.77M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$3.05M |
| 4 |
Renaissance Technologies
New York
|
+$2.76M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.34M |
